Chronic Lymphocytic Leukemia

​​The role of BTK monotherapy
Bcl-2 inhibitor combinations
Biology and clonal evolution of CLL
Cellular therapies for CLL
Monoclonals and bispecifics in CLL  
Novel approaches to Richter’s transformation

CLL

Huang et al., Front Cell Dev Biol. 2021

2_illustr

Ocana et al., Oncotarget. 2017

Multiple Myeloma

​Smoldering myeloma and special populations
T-cell engagers in MM
CAR-T for MM
Predictive biomarkers and precision therapy

3_illustr

Brentjens and Curran. Hematology Am Soc Hematol Educ Program. 2017

mm

Van de Donk et al., Lancet Oncol. 2021

mm2

Lymphoma

Chemo-free therapy for DLBCL
Peripheral T-cell lymphoma
Mantle cell lymphoma
Marginal zone lymphoma
Waldenström macroglobulinemia
Follicular lymphoma
Hodgkin Lymphoma
Uncommon lymphoma subtypes
Bispecifics as monotherapy in B-cell lymphoma
Combination therapy for B-cell lymphoma

lymphoma

Mihalyova et al., Int J Mol Sci. 2021

lymphoma2

Leukemia and MDS/MPN

Acute myeloid leukemia
Acute lymphoblastic leukemia
Translational biology of AML, MDS, and MPN
Molecularly targeted therapies for AML, ALL, and MPN
Myelofibrosis
Mastocytosis
Hairy cell leukemia
Chronic neutrophilic leukemia
Large granular lymphocyte leukemia

leukemia

Gurney and O’Dwyer, Cancers. 2021

leukemia2

Figure 1. Myeloproliferative neoplasms and myelodysplastic syndromes.

4a_illustr

Figure 2. A schematic description of genotypic diversity in patients with myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).

4_illustr
5_illustr
6_illustr

Mullighan, Nat Genet. 2009